These highlights do not include all the information needed to use ARZERRA safely and effectively. See full prescribing information for ARZERRA.
ARZERRA (ofatumumab)
Injection, for intravenous infusion
Initial U.S. Approval: 2009
WARNING: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
See full prescribing information for complete boxed warning.
-
•
-
Hepatitis B Virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death. (5.2)
-
•
-
Progressive Multifocal Leukoencephalopathy (PML) resulting in death. (5.4)
RECENT MAJOR CHANGES
|
Boxed Warning
|
09/2013
|
|
Indications and Usage (1)
|
04/2014
|
|
Dosage and Administration (2)
|
04/2014
|
|
Warnings and Precautions (5)
|
04/2014
|
INDICATIONS AND USAGE
ARZERRA (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated:
-
•
-
in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate. ( 1.1)
-
•
-
for the treatment of patients with CLL refractory to fludarabine and alemtuzumab. ( 1.2)
DOSAGE AND ADMINISTRATION
-
•
-
Dilute and administer as an int
